New Data from the Global ENGAGE Registry, IN.PACT Admiral Global Study, and VeClose Study Among Key Presentations
LONDON and DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) today announced key clinical studies for its leading vascular interventional portfolio will be featured at the annual 2017 Charing Cross Symposium (CX), one of the world's largest educational meetings specializing in vascular and endovascular disease management, in London from April 25-28, 2017. This year, more than 40 presentations, cases and hands-on demonstration sessions will highlight Medtronic aortic, endoVenous, and peripheral devices.
The highly anticipated five-year durability data from the global ENGAGE Registry will be presented on Wednesday, April 26, 2017. Philippe Cuypers, M.D., of Catharina Hospital in Eindhoven, The Netherlands will report on the long-term performance of the Endurant® stent graft system in patients with abdominal aortic aneurysms (AAA).
Peter Holt, M.D., from St George's University of London will present on a new analysis that will utilize data from the ENGAGE Registry to inform clinicians' treatment decisions following endovascular aneurysm repair (EVAR). In two separate sessions, Prof. Hence Verhagen, M.D., Ph.D., of University Medical Center in Rotterdam, The Netherlands and Ross Milner, M.D., of University of Chicago will present on sub-analyses of complex patients1 from the ENGAGE Registry.
New sub-analyses from the IN.PACT Global Study will be unveiled in two "Podium First" presentations on Tuesday, April 25, 2017 focusing on real-world patient outcomes, including the durability, safety, and efficacy of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) to treat challenging and complex lesions in patients with peripheral artery disease. Gary Ansel, M.D., of OhioHealth Riverside Methodist Hospital in Columbus, Ohio, will present one-year results comparing standard IDE-like patients versus complex (wider criteria) patient cohorts.
Shortly following, Fabrizio Fanelli, M.D., EBIR, of Sapienza University of Rome, Italy will share findings from a subset analysis on the impact of calcification when patients with complete total occlusions and long lesions are treated with the IN.PACT Admiral DCB.
The VenaSeal(TM) closure system will be featured in two key clinical presentations, including the three-year results of Medtronic's pivotal VeClose study and 12-month results from the WAVES study, which is an independent, physician-sponsored study. Both data sets will be presented by Kathleen Gibson, M.D., of Lake Washington Vascular in Seattle on Tuesday, April 25, 2017. VenaSeal is a non-tumescent, non-thermal, and non-sclerosant procedure that uses a proprietary medical adhesive to close superficial veins of the lower extremities, such as the great saphenous vein (GSV), in patients with venous reflux.
"With clinical trials and registries that lead the industry in rigor and comprehensiveness, Medtronic is helping to create standards of care that underpin durable, consistent, and safe vascular procedures," said Tony Semedo, president and senior vice president of Medtronic's Aortic & Peripheral Vascular division. "We look forward to unveiling the latest clinical evidence across our interventional therapies at Charing Cross."
A schedule of selected Medtronic presentations appears below in chronological order in Greenwich Mean Time.
Tuesday, April 25, 2017
Wednesday, April 26, 2017
Thursday, April 27, 2017
In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
1 In the U.S., the Endurant II/IIs stent system is approved for neck lengths >= 10 mm and <= 60° infra-renal angulation.
Krystin Hayward Leong
Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.